Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imsidolimab in Hidradenitis Suppurativa
NCT04856930Phase 2Completed
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Jul 2021
- Primary completion
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of imsidolimab in hidradenitis suppurativa (HS), sponsored by Vanda Pharmaceuticals Inc.. Started Jul 2021; status: completed.
02
Drugs
imsidolimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT04856930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04856930.